Abstract
Introduction: Pure squamous carcinoma (SCC) is a rare entity in western regions. The management of SCC still remains similar to that of transitional carcinoma, although it is a different entity. A retrospective review can be helpful in understanding the biological behavior of this uncommon vesical tumour.Material and Methods: Nineteen consecutive cases of pure SCC of the bladder, not related to bilharziasis or spinal cord injury, are herein reported. Fifteen patients were submitted to radical cystectomy, combined with emasculation in 1 case and unilateral nephroureterectomy in another. Partial cystectomy was performed in 1 patient and transurethral resection followed by radiotherapy in 3 more cases. Involvement of prostatic urethra and upper urinary tract was evident in 9 (47.3%) and 5 patients (26.3%), respectively. Four patients were submitted to neoadjuvant chemotherapy and 1 to presurgical radiotherapy without any objective response. Adjuvant chemotherapy was performed in 3 patients. At a mean follow–up of 52 months, 6 patients (31.5%) are alive without any evidence of disease. SCC antigen was monitored in 5 patients. The possible role of this marker in bladder SCC is discussed.Conclusions: Invasion of the upper urinary tract and prostatic urethra seems more common in SCC than in transitional cell carcinoma. Distant metastases are rare. Most patients die after attempts of locoregional control of the tumor have failed. Extensive surgery is recommended. Preoperative radiotherapy should be considered since pelvic recurrences are the leading cause of progression in squamous cell carcinoma.
References
1.
Groeneveld AE, Marszalek WW, Heyns CF: Bladder cancer in various population groups in the greater Durban area of KwaZulu–Natal, South Africa. Br J Urol 1996;78:205–208.
2.
Fadl Elmula I, Gorunova L, Lundgren R, Mandahl N, Forsby N, Mitelman F, Heim S: Chromosomal abnormalities in two bladder carcinomas with secondary squamous cell differentiation. Cancer Genet Cytogenet 1998; 102:125–130.
3.
Kaufman JM, Fam B, Jacobs SC, Galibondo F, Yalla S, Kane JP, Rossier AB: Bladder cancer and squamous metaplasia in spinal cord injury patients. J Urol 1977;118:967.
4.
Navon JD, Soliman H, Khonsari F, Ahlering T: Screening cystoscopy and survival of spinal cord injured patients with squamous cell cancer of the bladder. J Urol 1997;157:2109– 2111.
5.
Stonehill WH, Goldman HB, Dmochowski RR: The use of urine cytology for diagnosing bladder cancer in spinal cord injured patients. J Urol 1997;157:2112–2114.
6.
Locke JR, Hill DE, Walzer Y: Incidence of squamous cell carcinoma in patients with long term catheter drainage. J Urol 1985;133:1034.
7.
Sene AP, Massey JA, McMahon RTF, Carroll RNP: Squamous cell carcinoma in a patient on clean intermittent self catheterization. Br J Urol 1990;65:213–214.
8.
Zaidi SZ, Theaker JM, Smart CJ: Squamous cell carcinoma in a patient on clean intermittent self–catheterization (case report). Br J Urol 1997;80:352–353.
9.
Brenner DW, Yore LM, Schellhammer PF: Squamous cell carcinoma of bladder after successful intravesical therapy with bacillus Calmette–Guerin. Urology 1989;34:93–95.
10.
Takayama K, Kumazawa J, Minoda K: Bladder tumour occurring in the contracted bladder following urinary tract tuberculosis. Eur Urol 1986;712:448.
11.
Stein JP, Skinner EC, Boyd SD, Skinner DG: Squamous cell carcinoma of the bladder associated with cyclophosphamide therapy for Wegener’s granulomatosis: A report of 2 cases. J Urol 1993;149:588–589.
12.
Tatsura H, Ishiguro Y, Okamura T, Kohri K: Bladder squamous cell carcinoma with human papilloma virus type 6 (HPV 6). Int J Urol 1995;2:347–349.
13.
Gaarenstroom KN, Bonfrer JM, Kenter GG, Korse CM, Hart AA, Trimbos JB, Helmerhorst TJ: Clinical value of pretreatment serum Cyfra 21–1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer. Cancer 1995;76:807– 813.
14.
Thörn M, Bergström R, Johansson AM, Ramström L, Persson I, Malmström PU: Trends in urinary bladder cancer incidence in Sweden 1960–93 with special reference to histopathology, time period, birth cohort, and smoking. Cancer Causes Control 1997;8:560–567.
15.
Brennan JA, Boyle JO, Koch WM, Goodman SN, Hruban RH, Eby YJ, Couch MJ, Forastiere AA, Sidransky D: Association between cigarette smoking and mutation of the p53 gene in squamous–cell carcinoma of the head and neck. N Engl J Med 1995;332:712–717.
16.
Jones MA, Bloom HJG, Williams G, Trott PA, Wallace DM: The management of squamous cell carcinoma of the bladder. Br J Urol 1980; 52:511.
17.
Wu RL, Osman I, Wu XR, Lu ML, Zhang ZF, Liang FX, Hamza R, Scher H, Cordon Cardo C, Sun TT: Uroplakin II gene is expressed in transitional cell carcinoma but not in bilharzial bladder squamous cell carcinoma: Alternative pathways of bladder epithelial differentiation and tumor formation. Cancer Res 1998;58: 1291–1297.
18.
Tannenbaum SI, Carson CC, Tantum A, Paulson DF: Squamous cell carcinoma of urinary bladdder. Urology 1983;22:597.
19.
Debbagh A, Bennani S, Hafiani M, el Mrini M, Benjelloun S: Epidermoid carcinoma of the bladder: A propos of 14 cases. Ann Urol (Paris) 1997;31:199–203.
20.
Kenworthy P, Tanguay S, Dinney CPN: The risk of upper urinary tract recurrence following cystectomy in patients with transitional cell carcinoma involving the distal ureter. J Urol 1996;155:501–503.
21.
Clayman RV, Lange PH, Fraley EE: Cancer of the upper urinary tract; in Javadpour N (ed): Principles and Management of Urologic Cancer. Baltimore, Williams & Wilkins, 1983, pp 544–559.
22.
Shaaban AA, Tribukait B, El–Bedeiwy AFA, Ghoneim MA: Characterization of squamous cell bladder carcinoma by flow cytometric deoxyribonucleic acid analysis: A report of 100 cases. J Urol 1990;144:879.
23.
Celis JE, Rasmussen HH, Vorum H, Madsen P, Honore B, Wolf H, Orntoft TF: Bladder squamous cell carcinomas express psoriasin and externalize it to the urine. J Urol 1996;155: 2105–2112.
24.
Lara PC, Cuyas JM: The role of squamous cell carcinoma antigen in the management of laryngeal and hypopharyngeal cancer. Cancer 1995;76:758–764.
25.
Tsukamoto T, Kumamoto Y, Ohmura K, Miyao N, Nammbu A, Takagi Y, Itoh N: Squamous cell carcinoma associated antigen in uroepithelial carcinoma. Urology 1992;40:477–483.
26.
Ostergaard M, Rasmussen HH, Nielsen HV, Vorum H, Orntoft TF, Wolf H, Celis JE: Proteome profiling of bladder squamous cell carcinomas: Identification of markers that define their degree of differentiation. Cancer Res 1997;57:4111–4117.
27.
Ghoneim MA, el Mekresh MM, el Baz MA, el Attar IA, Ashamallah A: Radical cystectomy for carcinoma of the bladder: Critical evaluation of the results in 1,026 cases. J Urol 1997; 158:393–399.
28.
Richie JP, Waisman J, Skinner DG, Dretler SP: Squamous carcinoma of the bladder: Treatment by radical cystectomy. J Urol 1976;115: 670.
29.
Crawford ED, Das S, Smith JA Jr: Preoperative radiation therapy in the treatment of bladder cancer. Urol Clin N Am 1987;14:781.
30.
Ghoneim MA, Ashamallah, AK, Awaad HK, Whitmore WF Jr: Randomized trial of cystectomy with or without preoperative radiotherapy for carcinoma of the bilharzial bladder. J Urol 1985;134:266.
31.
Swanson DA, Liles A, Zagars GK: Preoperative irradiation and radical cystectomy for stages T2 and T3 squamous cell carcinoma of the bladder. J Urol 1990;143:37.
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
